Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab with Lenvatinib or Chemotherapy in Advanced Biliary Tract Cancer
NCT06362317Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Mar 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lenvatinib in biliary tract cancer (BTC) (3 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Objective Response Rate at 6 months. Started Mar 2024; status: recruiting.
02
Drugs
lenvatinib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06362317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06362317.